Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Substantially Pure Carfilzomib Amorphous for Generic Launch

Substantially Pure Carfilzomib Amorphous for Generic Launch

Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumour cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumour growth.

Dr. Reddy's API Offering

Dr. Reddy’s Carfilzomib API is a notable example of the technical capabilities of product development. It offers our customers access to a generic API that shows distinct features of having optimal consumption co-efficient in line with the green chemistry concept and superlative quality resulting from a robust process at scale.

  • We manufacture Carfilzomib amorphous API at our cGMP API manufacturing facility, successfully inspected by international regulatory authorities - USFDA, KFDA, WHO- GMP, Russian Federation, and ANVISA (document-based inspection completed and certificate is available).
  • To achieve high supply assurance, our key starting materials (KSM) are sourced domestically, and one is from China.
  • Continuous improvement is in place to achieve quality and supply excellence.
  • The current batch size is about 1.5 kg (Per customer requirement, discrete lots can be supplied).

To learn more about our API offerings, please read the product alert Carfilzomib API by filling out the contact form below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.



Book your slot to
explore our API solutions firsthand!

Schedule a meeting at CPHI China